論文・出版
Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: A multi-institution survey.
河口浩介、石黒 洋、森田智視、中村清吾、大野真司、増田慎三、岩田広治、青儀健二郎、黒井克昌、戸井雅和； Japan Breast Cancer Research Group (JBCRG)
Breast Cancer Research and Treatment, 130(2) : 627-634, 2011. doi: 10.1007/s10549-011-1641-9.
Economic evaluation of the 21-gene signature (Oncotype DX(®)) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03).
近藤正英、星 淑玲、山中竹春、石黒 洋、戸井雅和
Breast Cancer Res Treat. 2011 Jun;127(3):739-49. doi: 10.1007/s10549-010-1243-y.
Japan Breast Cancer Research Group (JBCRG)
黒井克昌、柏 喜代美、戸井雅和、中村清吾、岩田広治、大野真司、増田慎三、青儀健二郎、佐藤信昭、笹野公伸
腫瘍内科 6(4): 360-368, 2010
Clinical Significance of the 21-Gene Signature (Oncotype DX) in Hormone Receptor-Positive Early Stage Primary Breast Cancer in the Japanese Population
Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S, Nakayama T, Kashiwaba M, Kamigaki S, Kuroi K; and the Japan Breast Cancer Research Group-Translational Research
Cancer 2010, July 1: 3113-3118. doi: 10.1002/cncr.25206.
JBCRG-07
増田慎三
Cancer Board乳癌 3(1): 92, 2010
JBCRG-M02
黒井克昌
Cancer Board乳癌 3(1): 91, 2010.
「術前化学療法; 治療効果の評価」みんなに役立つ乳癌の基礎と臨床(戸井雅和 編集)
黒井克昌
医薬ジャーナル社, p654-662, 2009
術前薬物療法の新展開―JBCRG studyのあゆみ
山城大泰 戸井雅和
医学のあゆみ Vol 230, No1,p57-61, 2009
SUPREMO(BIG2-04)試験.
黒井克昌
Cancer Board乳癌 2(1): 68, 2009.
ALTTO試験.
黒井克昌
Cancer Board乳癌 1(1): 58, 2008